Regulatory Updates in Mexico and Argentina: What You Need to Know

Mexican and Argentine regulations for pharmaceuticals and medical devices just got an overhaul. If you work in these industries or plan to export to these regions, you might want to pay attention.

Mexico’s New Guidelines for Pharmaceuticals and Medical Devices

On March 20, Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) rolled out new guidelines. The focus keyword here is “new regulations.”

Key Points of Mexico’s New Guidelines

• Recognition of International GMP Certifications: Mexico now recognizes GMP certificates from Brazil, Argentina, Canada, Colombia, Chile, Cuba, and the United States.
• Digitalization of Processes: Under PIC/S and the US-Mexico-Canada Agreement (USMCA), processes will now undergo full digital transformation.
• ISO Certification Recognition: Medical devices must comply with ISO 13485:2016, a quality management system standard.

What This Means for Manufacturers

1. Streamlined Processes: Manufacturers can expect easier certification processes.
2. Extended Validity: COFEPRIS-issue GMP certifications now last 30 months, extendable for another 15 months.
3. Stronger IP Protections: A new agreement with Mexico’s patent office aims to boost generic drug accessibility without violating patents.

Participating in International Standards

COFEPRIS is aligning its standards with global authorities like WHO and is part of initiatives to harmonize international regulations. This boosts confidence in Mexico’s regulatory framework for pharmaceuticals and medical devices.

What’s Happening in Argentina

Just a few days before Mexico’s announcement, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) dropped new guidelines for biosimilars.

Core Aspects of Argentina’s Biosimilar Guidelines

• Updated Efficacy Requirements: Focuses on demonstrating similarity in efficacy compared to the reference product.
• Inclusion of Recombinant DNA Products: Covers products derived from recombinant DNA technology, excluding vaccines.
• Clinical and Non-Clinical Study Frameworks: Involves various study types such as pharmacokinetics, pharmacodynamics, and immunogenicity.

Implications for the Argentine Market

• This move opens the door for more biosimilars in the market.
• It’s designed to cut costs and improve access to expensive treatments.
• The guideline promotes innovation and efficiency in the local pharmaceutical sector.

How This Impacts Korean Exporters

Korean Ministry of Food and Drug Safety, respected globally for its regulatory capabilities, is seizing these opportunities. The new guidelines may allow easier entry for Korean medical exports into Latin America.

What Korean Companies Can Do

• Leverage Recognition: Use Korea’s recognized regulatory capabilities to enter these markets.
• Align with International Standards: Aligning with global standards can ease exports to these regions.
• Explore Partnerships: Consider partnerships with local companies to navigate these new guidelines.

Expected Outcomes

• Increased Export Opportunities: Korean companies could see expanded export capabilities in the region.
• Strengthened Global Position: Korea’s involvement in bodies like IMDRF highlights its strong international standing.

This regulatory update isn’t just bureaucratic noise. It’s a chance to align your strategies and enter an expanding market. Stay updated and plan your next move to capitalize on these changes.